Innovent Biologics Inc., a leading biopharmaceutical company, announced that its New Drug Application (NDA) for mazdutide, a dual glucagon/glucagon-like peptide-1 receptor agonist, has been accepted for review by China's National Medical Products Administration (NMPA). This regulatory review pertains to mazdutide's use in glycemic control for Chinese adults with type 2 diabetes. The Phase 3 DREAMS-1 clinical study demonstrated significant benefits in glycemic control, weight loss, and improvements in cardiovascular, renal, and metabolic indicators. Innovent Biologics anticipates that, upon approval, mazdutide will offer a superior treatment option for the vast number of type 2 diabetes patients in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.